At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRDF Cardiff Oncology, Inc.
Post-Market Trading 06-28 17:04:58 EDT
2.22
-0.11
-4.72%
盘后2.22
+0.000.00%
16:46 EDT
High2.33
Low2.21
Vol5.85M
Open2.29
D1 Closing2.33
Amplitude5.15%
Mkt Cap99.29M
Tradable Cap91.79M
Total Shares44.72M
T/O13.01M
T/O Rate14.14%
Tradable Shares41.35M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.